<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554695</url>
  </required_header>
  <id_info>
    <org_study_id>15-002313</org_study_id>
    <nct_id>NCT02554695</nct_id>
  </id_info>
  <brief_title>Osteoclast Inhibition and Bone Formation</brief_title>
  <official_title>Effects of Age and Osteoclast Inhibition on Bone Formation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol addresses: 1) How gene expression changes in bone cells are affected by aging?
      2) Is aging associated with decreased signaling between bone cells? 3) How does treatment
      with the osteoporosis medication denosumab affect bone cell signaling?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol collectively addresses the following goals: 1) What are the changes in gene
      expression in osteoblasts and osteocytes that lead to impaired bone formation with aging; 2)
      Since recent work from the investigators' group has demonstrated that osteoclasts produce a
      number of growth factors and cytokines (coupling factors) that enhance osteoblast
      proliferation and/or differentiation, is aging associated with reduced osteoclast coupling
      factor production; and 3) If osteoclasts are markedly reduced using the FDA-approved
      medication for osteoporosis, denosumab, how does that effect the quantity of coupling factors
      in the bone microenvironment and the target genes of these coupling factors in osteoblasts?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2015</start_date>
  <completion_date type="Actual">October 25, 2016</completion_date>
  <primary_completion_date type="Actual">October 25, 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression changes in bone cells</measure>
    <time_frame>3 months</time_frame>
    <description>Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteoclast-osteoblast coupling factor changes</measure>
    <time_frame>3 months</time_frame>
    <description>Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Bone Loss</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single subcutaneous injection of placebo (normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single subcutaneous injection of denosumab 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>young normal premenopausal women</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous saline injection</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>single subcutaneous injection of denosumab 60 mg</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  normal premenopausal women aged 25-40 years

               -  normal postmenopausal women aged 60-80 years

               -  at least 5 yrs since their last menses

               -  follicle stimulating hormone (FSH) &gt; 20 IU/L

          -  Exclusion Criteria:

               -  Abnormality in any of the screening laboratory studies

               -  Presence of significant liver or renal disease

               -  Malignancy (including myeloma)

               -  Malabsorption

               -  Diabetes

               -  Hypoparathyroidism

               -  Hyperparathyroidism

               -  Acromegaly

               -  Cushing's syndrome

               -  Hypopituitarism

               -  Severe chronic obstructive pulmonary disease

               -  Undergoing treatment with any medications that affect bone turnover, including
                  the following:

          -  adrenocorticosteroids (&gt; 3 months at any time or &gt; 10 days within the previous yr)

          -  anticonvulsant therapy (within the previous year)

          -  pharmacological doses of thyroid hormone (causing decline of thyroid stimulating
             hormone below normal)

          -  calcium supplementation of &gt; 1200 mg/d (within the preceding 3 months)

          -  bisphosphonates (within the past 3 yrs)

          -  denosumab

          -  estrogen (E) therapy within the past year

          -  treatment with a selective E receptor modulator within the past year

          -  teriparatide within the past yr

               -  Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm)

               -  Recent (within the past 6 months) fracture

               -  Serum 25-hydroxyvitamin D levels of &lt; 20 ng/ml
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sundeep Khosla, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>adrenergic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

